RxDoctor Payments Data

Sergio Morello, MD

Ophthalmology · Sunrise, FLNPI 1376971556

Payments from drug & device makers

$10,448in general payments, 2019–2025

Across 180 payments — averaging $58.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$3K
  • Alcon$2K
  • AbbVie$2K
  • NEW World Medical,inc.$662
  • Amgen$447
  • Bausch & Lomb Americas Inc.$366
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$3,61935%
  • Food & beverage$6,83065%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,448 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$143,323
Medicare patients
233
Services billed
1,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf50$36,984
RestasisCyclosporine42$31,702
Prednisolone Acetate260$13,732
CombiganBrimonidine Tartrate/Timolol22$9,678
XiidraLifitegrast12$8,714
LumiganBimatoprost13$7,883
SimbrinzaBrinzolamide/Brimonidine Tart20$4,873
MoxifloxacinMoxifloxacin Hcl147$3,583
Tobradex StTobramycin/Dexamethasone13$3,120
Cyclosporine13$2,460
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$2,433
Ketorolac Tromethamine92$2,184
Latanoprost185$2,024
Doxycycline Hyclate47$1,963
Brimonidine Tartrate39$1,250

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan$1,682$49,26377 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$366$45,69862 claims
AlconSimbrinza$2,477$4,87320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Sunrise

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →